Results 1 to 10 of about 15,139,370 (299)

Clinical assessment of immune-related adverse events

open access: yesTherapeutic Advances in Medical Oncology, 2018
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance.
Aaron Sosa   +4 more
doaj   +6 more sources

Metabolic syndrome and immune-related adverse events [PDF]

open access: yesCancer Immunology, Immunotherapy
Background Years into the immune checkpoint inhibitor (ICI) era, immune-related adverse events (irAE) remain largely unpredictable. Prior studies have examined irAE associations with weight and metabolic diseases, yielding mixed findings.
Katherine Lei   +12 more
doaj   +4 more sources

Immune-related adverse events: A bibliometric analysis

open access: yesFrontiers in Immunology, 2022
BackgroundDespite providing clinical benefit, immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in a number of patients.
Shi-Tao Jiang   +5 more
doaj   +3 more sources

Gastrointestinal disorders as immune-related adverse events [PDF]

open access: yesExploration of Targeted Anti-tumor Therapy, 2021
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy.
Daniele Balducci   +4 more
doaj   +3 more sources

Immune-Related Adverse Events of the Gastrointestinal System

open access: yesCancers, 2023
Immune checkpoint inhibitors (ICI) are a form of immunotherapy that have revolutionized the treatment of a number of cancers. Specifically, they are antibodies targeted against established and emerging immune checkpoints, such as cytotoxic T-cell antigen 4 (CTLA4), programmed cell death ligand 1 (PD-L1) and programmed cell death 1 protein (PD-1) on CD8-
Nicolaides, Steven, Boussioutas, Alex
openaire   +3 more sources

Immune-related adverse events of checkpoint inhibitors [PDF]

open access: yesNature Reviews Disease Primers, 2020
Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs).
Ramos Casals, Manuel   +9 more
core   +7 more sources

Pathological perspectives on immune-related adverse events

open access: yesImmunological Medicine
Over the past decade, immune checkpoint inhibitors (ICIs) have moved from the research setting into routine clinical practice. Their use has expanded from single-agent therapy to combination regimens with cytotoxic chemotherapy, targeted agents, and ...
Terufumi Kubo   +7 more
doaj   +3 more sources

Immune-related adverse events of immune checkpoint inhibitors: a review

open access: yesFrontiers in Immunology, 2023
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved.
Qinan Yin   +15 more
doaj   +3 more sources

Immune Responses in Checkpoint Inhibitor–Associated Cardiovascular Immune–Related Adverse Events [PDF]

open access: yesJACC. CardioOncology
Although immune checkpoint inhibitors have improved cancer outcomes, their use can trigger autoimmune toxicities affecting essentially any organ system.
Kerry L. Reynolds, MD   +13 more
doaj   +2 more sources

In a nutshell: Haematological immune‐related adverse events

open access: yesBritish Journal of Haematology
Summary The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this ‘nutshell review’, we summarize the most common haematological immune‐related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and address current evidence regarding ICI rechallenge.
Rebecca K. Leaf, Jodi V. Mones
openaire   +3 more sources

Home - About - Disclaimer - Privacy